publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
chest
special
featur
epsi
acut
lung
injuri
ali
ard
contribut
substanti
expand
burden
critic
ill
within
unit
state
epidemiolog
estim
suggest
incid
patient
annual
aliard
compar
larg
grow
incid
sepsi
morbid
mortal
diseas
process
likewis
stagger
inhospit
death
rate
rang
studi
ard
wherea
sepsi
kill
nearli
onehalf
sever
affect
patient
ultim
surviv
initi
hospit
qualiti
life
often
dramat
reduc
econom
impact
consider
sepsi
instanc
contribut
nearli
billion
toward
burgeon
cost
us
critic
care
deliveri
pathophysiolog
perspect
sepsi
ali
ard
character
abnorm
enhanc
coagul
dysregul
often
injuri
host
immun
microvascular
dysfunct
tissu
necrosi
increas
evid
suggest
hematolog
derang
associ
may
import
contributor
diseas
sever
larg
infl
uenc
alter
platelet
leukocyt
function
although
plateletmedi
thrombosi
implic
pathobiolog
host
plateletassoci
effect
infl
uenc
natur
histori
understand
pluripotenti
impact
platelet
immunopatholog
specifi
c
role
develop
progress
sepsi
acut
lung
injuri
ard
contribut
substanti
expand
burden
critic
ill
within
icu
process
character
myriad
injuri
event
includ
apoptosi
microvascular
dysfunct
abnorm
coagul
dysregul
host
immun
recent
plateletslong
consid
mere
effector
thrombosisbeen
implic
infl
ammatori
condit
pathobiolog
diseas
process
grow
bodi
evid
suggest
promin
role
maladapt
platelet
activ
aggreg
sepsi
ard
begun
underscor
pluripotenti
infl
uenc
platelet
outcom
critic
ill
platelet
enhanc
vascular
injuri
thrombot
mechan
also
appear
help
orchestr
patholog
immun
respons
pivot
player
facilit
leukocyt
recruit
vulner
tissu
event
contribut
organ
damag
poor
patient
outcom
still
plagu
care
highrisk
individu
understand
role
platelet
critic
ill
also
highlight
potenti
develop
risk
stratifi
cation
schema
use
novel
target
therapi
might
alter
natur
histori
sepsi
acut
lung
injuri
ard
futur
studi
adenosin
platelet
polyphosph
platelet
transcriptomeproteom
also
add
consider
abil
unravel
mysteri
versatil
platelet
abbrevi
adp
adenosin
diphosph
ali
acut
lung
injuri
crp
creactiv
protein
gp
iibiiia
glycoprotein
iibiiia
pci
percutan
coronari
intervent
vwf
von
willebrand
factor
activ
platelet
thromboxan
induc
aggreg
vascular
smooth
muscl
contract
stimul
adenosin
diphosph
adp
receptor
platelet
surfac
result
alter
platelet
shape
support
platelet
aggreg
metabol
prime
armamentarium
platelet
extend
beyond
cell
surfac
receptor
howev
platelet
also
express
releas
varieti
adhes
molecul
mitogen
factor
vasoact
compound
play
key
role
modul
endotheli
function
aggreg
cellular
interact
compound
includ
cytoplasm
substanc
serotonin
epinephrin
norepinephrin
nitric
oxid
vascular
endotheli
growth
factor
transform
growth
factor
b
selectin
interact
cell
surfac
glycoconjug
mediat
adh
sion
cellular
commun
mitochondri
lysosom
store
releas
potent
glycosidas
proteas
cation
protein
platelet
also
contain
granul
releas
import
contributor
coagul
dens
granul
releas
nonprotein
molecul
includ
adp
calcium
serotonin
modul
infl
ammatori
thrombot
process
tabl
well
known
platelet
primari
effector
cell
hemostasi
role
thrombosi
vascular
repair
well
establish
four
main
phase
govern
platelet
function
activ
adhes
aggreg
secret
influenc
substanc
includ
thrombin
collagen
epinephrin
vasopressin
plateletactiv
factor
arachidon
acid
metab
olit
releas
site
tissu
injuri
platelet
activ
undergo
robust
rheolog
transform
fig
compon
suben
dotheli
matrix
becom
expos
circul
blood
platelet
glycoprotein
critic
ill
vital
import
clinician
investig
hope
improv
care
highrisk
patient
platelet
anucl
cell
myeloid
origin
continu
fl
ow
quiescent
state
throughout
human
vasculatur
deriv
megakaryocyt
circul
platelet
readi
perform
myriad
hemostat
infl
ammatori
repar
task
activ
condit
heighten
demand
platelet
product
increas
much
summon
tissu
injuri
infl
ammat
amplifi
ed
platelet
offens
exert
infl
uenc
varieti
cell
directli
releas
highli
potent
intracellular
constitu
platelet
recruit
adhes
orchestr
number
special
chemokin
adhes
molecul
receptor
particular
platelet
express
cell
surfac
receptor
call
integrin
integrin
make
larg
famili
receptor
constitut
express
surfac
mani
cell
whose
job
facilit
celltocel
celltoextracellular
matrix
interact
perhap
well
known
abund
platelet
integrin
glycoprotein
iibiiia
gp
iibiiia
receptor
follow
cellular
activ
gp
iibiiia
bind
fi
brinogen
fi
brin
ligand
mediat
adhes
event
stimul
platelet
aggreg
integrin
play
key
role
adhes
aggreg
thrombu
format
vascular
repair
addit
integrin
number
gproteincoupl
receptor
present
platelet
surfac
promot
platelet
activ
chang
platelet
rheolog
enhanc
aggreg
proteaseactiv
receptor
exampl
play
pivot
role
platelet
shown
facilit
leukocyt
respons
larg
infl
uenc
pselectin
promot
leukocyteplatelet
bind
although
platelet
interact
leukocyt
subpopul
intim
relationship
neutrophil
seem
drive
primari
role
host
immun
endothelialbound
platelet
induc
secondari
captur
neutrophil
fi
rst
facilit
plateletneutrophil
interact
direct
subsequ
neutrophilendotheli
cell
contact
neutrophil
also
capabl
roll
along
templat
adher
plateletsan
event
regul
numer
adhes
receptor
promot
shear
forc
alter
cellular
structur
roll
phenomenon
thought
mediat
larg
pselectin
direct
leukocyt
adher
support
leukocyt
transmigr
directli
site
injuri
clinic
perspect
alter
platelet
number
function
frequent
recogn
associ
critic
ill
particular
develop
thrombocytopenia
commonplac
incid
rang
nearli
across
spectrum
intens
care
set
present
thrombocytopenia
independ
associ
increas
morbid
mortal
von
willebrand
factor
vwf
mediat
intens
adhes
process
platelet
aggreg
fi
rmli
ensu
larg
support
gp
iibiiia
receptor
event
ultim
reinforc
potent
milieu
vasoact
compound
secret
galvan
platelet
offens
platelet
long
consid
mani
vital
particip
immun
process
henc
potenti
key
instig
number
common
infl
ammatori
diseas
activ
platelet
releas
numer
secretori
product
shown
express
multitud
receptor
involv
infl
ammatori
respons
tabl
atherosclerosi
instanc
activ
platelet
releas
adhes
ligand
pselectin
pselectin
capabl
creat
phospholipidrich
platform
facilit
recruit
mononuclear
cell
lymphocyt
atherosclerot
plaqu
platelet
activ
associ
enhanc
cytokin
express
infl
ammatori
condit
includ
acut
coronari
syndrom
coronari
stent
restenosi
solid
organ
transplant
reject
platelet
also
interact
directli
infl
ammatori
cell
help
engin
physiolog
patholog
immun
event
leukocyt
instanc
known
play
import
role
host
defens
recruit
site
infl
ammat
although
critic
help
defend
host
invad
gawaz
colleagu
found
plasma
patient
sepsi
increas
adhes
aggreg
normal
platelet
cultur
endothelium
mavrommati
et
al
later
show
platelet
activ
significantli
increas
patient
sepsi
compar
healthi
control
subject
other
demonstr
sepsi
result
increas
pselectin
express
hand
platelet
function
aggregometri
fl
ow
cytometri
shown
decreas
studi
yaguchi
et
al
boldt
et
al
demonstr
aggreg
decreas
time
cohort
trauma
patient
later
develop
sepsi
recent
human
murin
platelet
shown
express
tolllik
receptor
facilit
platelet
migrat
deposit
tissu
sepsi
possibl
pattern
recognit
receptor
may
repres
uniqu
mechan
organ
dysfunct
develop
sever
infect
research
howev
necessari
clarifi
associ
acquir
defici
plasma
proteas
also
may
support
enhanc
platelet
activ
describ
sepsi
system
infl
ammatori
respons
syndrom
nguyen
colleagu
report
function
decreas
principl
physiolog
modul
vwf
human
plasmaamong
patient
sepsi
other
demonstr
stepwis
declin
activ
parallel
extent
infl
ammatori
respons
small
sampl
critic
ill
icu
patient
burden
evid
seem
support
notion
platelet
activ
aggreg
increas
sepsi
result
acceler
platelet
respons
mechan
result
tissu
injuri
less
well
defi
ned
although
small
studi
shown
platelet
caus
microvascular
obstruct
tissu
hypoperfus
impair
cardiac
contractil
endotheli
dysfunct
consequ
plateletinduc
apoptosi
like
number
poorli
defi
ned
patholog
event
contribut
untoward
infl
uenc
platelet
septic
outcom
one
mechan
injuri
sepsi
may
center
around
aforement
role
platelet
play
leukocyt
recruit
although
like
repres
adapt
respons
facilit
host
defens
mount
evid
suggest
maladapt
plateletleukocyt
interact
result
tissu
injuri
studi
polymicrobi
sepsi
asaduzzaman
et
al
found
signifi
cant
lung
injuri
result
enhanc
pulmonari
less
well
establish
causal
relationship
thrombocytopenia
critic
care
outcom
whether
thrombocytopenia
repres
platelet
activ
consumpt
primari
patholog
event
mere
serv
marker
diseas
sever
unknown
uncertainti
consequ
myriad
condit
known
infl
uenc
circul
platelet
number
heterogen
icu
patient
render
diffi
cult
investig
account
potenti
confound
clinic
research
critic
ill
individu
may
diminish
platelet
product
due
medic
effect
bone
marrow
suppress
nutrit
defici
infect
also
may
enhanc
platelet
elimin
due
splenic
sequestr
consumpt
relat
dissemin
intravascular
coagulopathi
thrombocytopenia
result
hemodilut
immunolog
mediat
thrombocytopenia
spuriou
thrombocytopenia
also
introduc
complex
patient
evalu
icu
cours
thrombocytopenia
poor
prognost
marker
rather
power
predictor
mortal
patient
sepsi
septic
shock
magnitud
platelet
reduct
seem
correl
sever
ill
ali
ard
develop
clinic
thrombocytopenia
infl
uenc
outcom
poorli
understood
small
patient
seri
repres
noncontemporari
treatment
era
thrombocytopenia
believ
occur
mani
patient
ard
degre
thrombocytopenia
shown
parallel
cours
progress
hypoxem
respiratori
failur
inconsist
associ
mortal
recent
thrombocytopenia
describ
promin
featur
among
patient
sever
acut
respiratori
syndrom
rapidli
progress
coronavirusassoci
respiratori
ill
result
global
outbreak
ali
shock
confl
ict
data
platelet
function
respons
stimuli
critic
ill
patient
sepsi
would
suggest
septic
milieu
part
infl
uenc
lipopolysaccharid
endotoxemia
promot
enhanc
platelet
aggreg
lead
microvascular
obstruct
tissu
injuri
other
argu
aggreg
platelet
respons
actual
decreas
patient
sepsi
wherea
still
other
suggest
activ
may
fact
enhanc
sepsi
signifi
cant
platelet
degranul
occur
sever
decompens
increas
neutrophil
adhes
activ
result
thromboxan
produc
plateletneutrophil
aggreg
effort
deplet
platelet
disrupt
aggreg
result
reduc
neutrophil
migrat
permeabl
improv
ga
exchang
better
surviv
enhanc
platelet
activ
secret
also
support
sever
clinic
preclin
studi
ali
ventil
stressinduc
model
ard
yime
et
al
demonstr
increas
express
vwf
glycoprotein
ib
pselectin
endotheli
surfac
rat
mice
lung
bronchoscop
studi
patient
lung
injuri
idel
colleagu
found
level
plateletspecifi
c
granul
protein
elev
bal
fl
uid
injur
tissu
directli
correl
degre
pulmonari
injuri
studi
critic
ill
patient
investig
found
vivo
platelet
activ
robust
among
acut
respiratori
failur
also
show
mark
platelet
dysfunct
character
impair
aggreg
prolong
bleed
time
typic
featur
individu
care
review
sever
current
use
evidencebas
therapi
ali
ard
provid
addit
insight
potenti
patholog
role
plateletmedi
event
host
clinic
studi
help
defi
ne
contemporari
treatment
strategi
critic
ill
sever
therapi
share
part
abil
modifi
mechan
platelet
activ
aggreg
perhap
wellvalid
strategi
reduc
mortal
use
lowtidalvolum
ventil
fact
use
injuri
hightidalvolum
ventil
shown
upregul
vwf
pselectin
express
use
lungprotect
posit
pressur
ventil
howev
associ
decreas
adpand
collagenmedi
platelet
aggreg
nitric
oxid
anoth
therapi
often
use
ardsali
despit
limit
data
support
routin
use
shown
decreas
platelet
aggreg
reduc
ing
fi
brinogen
bind
gp
iibiiia
receptor
well
controversi
use
corticosteroid
ard
associ
decreas
platelet
activ
activ
experiment
model
although
suggest
therapi
improv
lung
injuri
plateletmodifi
effect
alon
data
support
biolog
plausibl
consid
studi
impact
dysregul
platelet
activ
patient
outcom
fig
although
grow
evid
suggest
patholog
role
platelet
number
infl
ammatori
infiltr
plateletbound
neutrophil
investig
demonstr
inhibit
plateletassoci
neutrophil
recruit
mitig
form
endorgan
damag
help
establish
causal
relationship
plateletneutrophil
interact
patholog
injuri
seen
sever
sepsi
propos
platelet
recruit
neutrophil
site
tissu
injuri
infl
ammat
result
subsequ
damag
varieti
mechan
plateletneutrophil
aggreg
may
becom
trap
within
narrow
site
organ
microvasculatur
lead
region
ischemia
kirschenbaum
colleagu
instanc
show
format
aggreg
pronounc
effect
alter
blood
rheolog
patient
sepsi
process
investig
believ
contribut
significantli
impair
perfus
platelet
also
may
adher
directli
infl
ame
endotheli
cell
promot
secondari
captur
toxic
circul
leukocyt
mechan
support
sever
small
studi
target
inhibit
plateletspecifi
c
ligand
neutrophil
reliabl
attenu
sepsisassoci
endotheli
injuri
circul
plateletneutrophil
complex
plateletstimul
neutrophil
extracellular
trap
format
also
seen
patient
sepsi
neutrophil
extracellular
trap
believ
repres
subset
activ
neutrophil
enhanc
abil
adher
phagocytos
produc
injuri
superoxid
final
data
suggest
lymphotox
lymphoid
cell
apoptosi
may
result
sepsisinduc
alter
platelet
mrna
profi
le
dysregul
hemostasi
enhanc
infl
ammat
hallmark
pathophysiolog
event
associ
ali
ard
postmortem
seri
patient
ard
shown
platelet
deposit
within
damag
pulmonari
microvasculatur
commonplac
ultrastructur
examin
lung
patient
ard
consist
shown
platelet
accumul
plateletfi
brin
deposit
occur
within
pulmonari
arteri
arteriol
capillari
well
within
pulmonari
interstiti
alveolar
compart
affect
individu
sepsi
plateletneutrophil
interact
seem
play
domin
role
tissu
injuri
seen
ard
murin
model
acidinduc
lung
injuri
zarbock
colleagu
demonstr
tialli
reduc
anim
treat
aspirin
among
healthi
volunt
howev
littl
compel
evid
support
antiinfl
ammatori
effect
aspirin
studi
among
patient
acut
chronic
infl
ammatori
condit
yield
mix
result
patient
chronic
stabl
angina
instanc
aspirin
signifi
cantli
lower
crp
infl
ammatori
cytokin
level
convers
patient
chronic
ischem
heart
diseas
recent
myocardi
infarct
acut
coronari
syndrom
aspirin
fail
reliabl
reduc
crp
peripher
arteri
diseas
well
marker
plateletmedi
infl
ammat
signifi
cantli
decreas
aspirin
therapi
also
confl
ict
evid
regard
potenti
aspirin
mitig
patholog
infl
ammatori
interact
platelet
leukocyt
clopidogrel
clopidogrel
plavix
irrevers
antagonist
gproteincoupl
platelet
adp
receptor
shown
greater
infl
uenc
cardiovascular
risk
reduct
among
patient
heighten
inflammatori
state
post
hoc
analysi
clopidogrel
reduct
event
observ
trial
studi
prolong
clopidogrel
therapi
follow
percutan
coronari
intervent
pci
signifi
cant
rela
tive
risk
reduct
combin
end
point
death
myocardi
infarct
stroke
condit
includ
sepsi
ali
far
fewer
data
support
target
antiplatelet
strategi
therapeut
option
manag
affl
ict
patient
strategi
howev
without
histor
merit
year
cardiovascular
commun
espous
benefi
ts
antiplatelet
agent
reduc
infl
ammat
acut
chronic
atherosclerot
diseas
platform
novel
investig
burgeon
interest
platelet
therapeut
target
patient
critic
ill
aspirin
within
subset
patient
enrol
physician
health
studi
random
trial
aspirin
vs
b
caroten
primari
prevent
cardiovascular
diseas
use
aspirin
associ
signifi
cant
reduct
risk
myocardi
infarct
predominantli
among
patient
highest
creactiv
protein
crp
valu
fi
nding
among
fi
rst
piec
clinic
evid
suggest
possibl
antiinfl
ammatori
role
commonli
use
antiplatelet
therapi
aspirin
also
shown
inhibitori
effect
activ
nuclear
factor
k
b
transcript
factor
requir
express
gene
encod
varieti
infl
ammatori
molecul
mous
model
atherosclerosi
normal
enhanc
nuclear
factor
k
b
activ
substan
figur
infl
uenc
platelet
plateletneutrophil
interact
pathophysiolog
sepsi
b
ali
sepsi
platelet
may
stimul
tissu
injuri
hypoxia
cytokin
lp
endotoxemia
lead
microvascular
obstruct
cellular
necrosisapoptosi
enhanc
leukocyt
respons
ali
platelet
plateletneutrophil
complex
similarli
found
within
pulmonari
vasculatur
airway
interstiti
alveolar
compart
ali
acut
lung
injuri
lp
lipopolysaccharid
american
colleg
chest
physician
kimberli
henrick
march
chestjournalchestpubsorg
download
requir
surgeri
adjust
differ
baselin
characterist
diseas
sever
howev
antiplatelet
therapi
use
associ
substanti
reduc
mortal
group
singlecent
studi
hospit
patient
communityacquir
pneumonia
receiv
antiplatelet
agent
secondari
prevent
cardiovascular
diseas
win
et
al
found
antiplatelet
drug
use
associ
reduct
length
stay
need
icu
care
later
retrospect
studi
conduct
mix
medicalsurg
icu
investig
found
preexist
treatment
antiplatelet
agent
reduc
odd
ratio
mortal
nearli
fi
vefold
even
patient
sign
activ
bleed
includ
lifethreaten
intracrani
hemorrhag
transfusiondepend
anemia
still
strong
associ
antiplatelet
drug
improv
outcom
associ
robust
among
patient
greatest
diseas
sever
although
limit
retrospect
natur
analys
modest
design
challeng
data
still
speak
potenti
role
platelet
therapeut
target
among
heterogen
critic
care
popul
impact
antiplatelet
agent
circul
platelet
marker
infl
ammat
system
infect
yet
clarifi
ed
despit
increas
studi
anim
human
model
earli
studi
antiplatelet
drug
endotoxem
pig
pretreat
found
minim
effect
pathogenesi
escherichia
coli
induc
shock
despit
platelet
target
clinic
sepsi
ensu
anim
concomit
decreas
level
platelet
along
activ
coagul
fi
brinolyt
system
clopidogrel
also
demonstr
effect
hemostat
infl
ammatori
respons
pig
infus
e
coli
endotoxin
howev
specifi
calli
use
clopidogrel
anim
model
sepsi
sever
investig
report
platelet
activ
reduc
also
clinic
thrombocytopenia
attenu
clot
format
decreas
cytokin
upregul
mitig
neutrophil
recruit
may
minim
antiplatelet
agent
ali
ard
even
fewer
data
exist
regard
antiplatelet
strategi
critic
ill
patient
lung
injuri
target
platelet
deplet
disrupt
plateletneutrophil
interact
murin
model
ard
result
reduc
neutrophil
migrat
permeabl
improv
alveolar
ga
exchang
increas
surviv
aspirin
use
experiment
month
patient
highest
tertil
highsensit
crp
level
likewis
shorterterm
cardiovascular
event
reduc
follow
pci
patient
pretreat
clopidogrel
elev
baselin
crp
valu
unlik
aspirin
therapi
howev
clopidogrel
administr
shown
reduc
secret
adhes
ligand
block
format
plateletleukocyt
conjug
result
decreas
leukocyt
activ
patient
treat
pci
clopidogrel
reduc
adpand
thrombin
receptoractiv
peptideinduc
express
platelet
pselectin
evangelista
colleagu
show
clopidogrel
use
potent
inhibitori
effect
plateletdepend
product
reactiv
oxygen
speci
neutrophil
well
monocyt
express
tissu
factor
klinkhardt
et
al
found
moreprolong
clopidogrel
pretreat
could
signifi
cantli
reduc
volum
plateletmonocyt
plateletneutrophil
aggreg
follow
adp
stimul
effect
correl
directli
substanti
reduct
pselectin
express
similarli
clopidogrel
therapi
shown
reduc
plateletneutrophil
plateletmonocyt
conjug
patient
across
spectrum
vascular
diseas
antiplatelet
agent
confl
ict
data
come
studi
gp
iibiiia
receptor
antagonist
infl
ammatori
condit
modest
level
receptor
blockad
actual
associ
increas
plateletmedi
proinfl
ammatori
effect
along
enhanc
express
pselectin
increas
releas
solubl
ligand
furthermor
although
synthet
smallmolecul
gp
iibiiia
inhibitor
eptifi
batid
integrilin
signifi
cantli
reduc
level
crp
h
compar
placebo
enhanc
suppress
platelet
iibiiia
receptor
integrilin
therapi
trial
level
subsequ
increas
beyond
baselin
h
follow
infus
hand
abciximab
reopro
chimer
fab
fragment
monoclon
antibodi
high
affi
niti
gp
iibiiia
receptor
found
suppress
usual
rise
level
circul
infl
ammatori
marker
follow
percutan
translumin
coronari
angioplasti
final
among
small
popul
patient
treat
tirofi
ban
aggrastat
data
larg
inconclus
gener
limit
studi
antiplatelet
therapeut
strategi
critic
care
popul
colleagu
found
antiplatelet
drug
associ
slight
reduct
mortal
among
patient
nonsurg
critic
ill
slightli
increas
mortal
rate
among
diseas
moreintegr
understand
platelet
biolog
undoubtedli
allow
improv
clarifi
cation
adapt
maladapt
infl
uenc
platelet
critic
ill
potenti
identifi
molecular
signatur
patholog
platelet
activ
also
could
provid
ambiti
platform
studi
patient
variat
diseas
respons
establish
novel
risk
stratifi
cation
tool
develop
futur
therapeut
target
critic
care
investig
practition
recent
begun
understand
true
versatil
human
platelet
concert
multidisciplinari
effort
unravel
mysteri
platelet
critic
ill
clearli
import
hope
minim
devast
impact
sepsi
ali
ard
everexpand
patient
popul
transfusionrel
ali
model
prevent
neutrophil
sequ
tration
howev
neutrophil
infi
ltrate
pulmonari
parenchyma
render
incap
caus
lung
toxic
studi
clearli
need
build
preliminari
data
order
clarifi
intrigu
potenti
therapeut
platelet
target
lung
injuri
popul
role
platelet
pathophysiolog
critic
ill
continu
elucid
particularli
respect
lung
injuri
understand
woefulli
incomplet
longer
anucl
cell
consid
mere
executor
thrombot
process
instead
clearli
key
contributor
host
immun
respons
although
initi
adapt
unregul
platelet
activ
sepsi
ali
ard
lead
organ
hypoperfus
patholog
tissu
injuri
poor
patient
outcom
whether
modul
platelet
respons
improv
high
morbid
mortal
associ
diseas
remain
seen
small
nonrandom
clinic
studi
antiplatelet
strategi
yield
mix
result
prompt
addit
investig
follow
heel
earli
discoveri
futur
studi
may
capit
relationship
platelet
platelet
receptor
human
critic
ill
build
circumstanti
evid
trial
contemporari
antiplatelet
therapi
investig
begun
focu
greater
attent
role
adenosin
myriad
receptor
pathobiolog
infl
ammat
condit
high
metabol
stress
seen
acut
tissu
injuri
sepsi
instanc
extracellular
adenosin
concentr
often
markedli
increas
adenosin
believ
play
import
role
prevent
neutrophil
infi
ltration
vulner
tissu
grow
bodi
data
suggest
possibl
role
adenosin
modul
adapt
immun
respons
critic
ill
likewis
increas
attent
direct
toward
infl
uenc
platelet
polyphosph
proinfl
ammatori
procoagul
mediat
acut
ill
recent
investig
shown
polyphosph
help
trigger
fi
brin
format
facilit
capillari
leakag
commonplac
among
icu
patient
polyphosph
also
seem
play
role
preserv
cellular
integr
modul
neutrophil
respons
infl
ammat
advanc
highthroughput
experiment
technolog
research
begin
character
full
complement
transcript
function
relev
protein
contribut
versatil
complex
platelet
human
